Zealand Pharma A/S

Hello and welcome to this Zeland Pharma Conference call. I would like to advise all participants that this call is being recorded. Thank you. I'd now like to welcome Anna Krasowska to begin the conference. Anna, over to you.

Thank you. Welcome and thank you for joining us today to discuss Zeland's interim results for the first quarter of 2023. With me today are the following members of Zeland's management team. Adam Stainsberg, President and Chief Executive Officer, Henrietta Wenneke, Chief Financial Officer, and David Kendall, Chief Medical Officer. You can find the related company announcement and interim report on our website at ZeelandPharma.com. As described on slide two, we will be making forward-looking statements that are subject to risks and uncertainties. With that, I will turn the call over to Adam Stainsberg, President and CEO. Adam?

Thank you, Anna, and thanks to everyone for joining today. I'll begin on slide three. We are now one year into my tenure as CEO at Sealand, and I'm very proud of what we have achieved. With a strong focus on R&D, we have successfully progressed our product candidates within both rare diseases and obesity. And despite the turbulent financial environment, we have significantly strengthen our balance sheet, and streamline operations. The strong momentum has continued into the first quarter of 2023. In our BCT portfolio, we achieved impressive clinical results in two P programs. We are very encouraged about the clinical outcome announced yesterday with Berengar Ingenheim for the dual gluagon GLP-1 receptor agonist BI456906. and excited about BI's regulatory interactions on phase three initiation. Our Amazin analog, CP8396, showed profound reductions in body weight after one week in the single ascending dose trial, and is now progressing well in the phase 1B multiple ascending dose trial. Importantly, we have also strengthened our balance sheet with the 1.5 billion Danish kroner from a direct issue in April, bringing on board a broad group of specialist investors. We now have a cash runway to mid-2026. Moving to slide four, we remain focused on our strategic objectives and our post-run exciting and catalyst-rich 2023. We are on track for two regulatory submissions in our rare disease programs, The first submission is expected here in the second quarter for dasyclurgan in babies and children with congenital hyperinsulinism or CHI. The second is for clopacritide in people living with short bowel syndrome and intestinal failure, expected in the second half of the year. We expect to see the strong momentum continuing with our obesity assets. including upcoming clinical data presentations and initiation and reporting of new clinical studies across the portfolio. Our strategy to pursue partnerships remains on track, and we will seek to continue to participate in the programs across the value chain where we can leverage our strengths and capabilities to maximize the value of each asset. Advancing to slide five, I will now turn over the call to our Chief Medical Officer, David Pendle, to discuss the recent top line results and our R&D pipeline.